U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars Fruergaard Jørgensen is stepping down from the Danish drugmaker.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Earnings grew barely 14% last quarter -- and over the past year, the stock has lost roughly half its value. The board cited these "recent market challenges Novo Nordisk has been facing ...

Weight loss drugmaker Novo Nordisk (NVO ... was made in light of the company’s recent market challenges and the performance of its stock since mid-2024. Jørgensen has agreed to serve as ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation ... seem to be weighing heavily on the stock — down less than 3% in trading ...